<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597219</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/10/0411</org_study_id>
    <nct_id>NCT01597219</nct_id>
  </id_info>
  <brief_title>Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers</brief_title>
  <acronym>UK-Haplo</acronym>
  <official_title>A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bloodwise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates stem cell transplants from partially mismatched donors in patients&#xD;
      with blood and bone marrow cancers. The trial will test two kinds of transplants - a full&#xD;
      intensity transplant using a high dose of radiotherapy and chemotherapy, and a reduced&#xD;
      intensity transplant with lower doses of chemotherapy and radiotherapy. Patients will be&#xD;
      entered for the treatment pathway that is most appropriate for their level of health and&#xD;
      fitness&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Acute Myeloid Leukaemia</condition>
  <condition>Acute Lymphoblastic Leukaemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myeloid Leukaemia</condition>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <condition>Acquired Bone Marrow Failure Syndromes</condition>
  <condition>Other Haematological Malignancies; Unrelated HSCT Indicated</condition>
  <arm_group>
    <arm_group_label>Reduced intensity haploidentical transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 &amp; +4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloablative haploidentical stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 &amp; -2 Stem cell transplant day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Reduced intensity haplodentical stem cell transplant</intervention_name>
    <description>Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 &amp; +4</description>
    <arm_group_label>Reduced intensity haploidentical transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Myeloablative haploidentical stem cell transplant</intervention_name>
    <description>Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 &amp; -2 Stem cell transplant day 0</description>
    <arm_group_label>Myeloablative haploidentical stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria&#xD;
&#xD;
          1. Eligible for an allogeneic transplant in line with the current BSBMT indications for&#xD;
             transplant criteria (http://bsbmt.org/indications-table/) accepted by Commissioners&#xD;
&#xD;
          2. Age 16-70&#xD;
&#xD;
          3. Adequate physical function&#xD;
&#xD;
               -  Cardiac: LVEF at rest ≥45%, or shortening fraction ≥25%&#xD;
&#xD;
               -  Hepatic: Bilirubin ≤35mmol/l; AST/ALT and alkaline phosphatase &lt;5 x ULN&#xD;
&#xD;
               -  Renal: Serum creatinine within normal range for age, or if serum creatinine&#xD;
                  outside normal range for age, creatinine clearance or GFR &gt;40ml/min/1.73m2&#xD;
&#xD;
               -  Pulmonary: FEV1, FVC, DLCO (diffusion capacity) &gt;50% predicted (corrected for&#xD;
                  haemoglobin); if clinically unable to perform pulmonary function tests then O2&#xD;
                  saturation &gt;92% on room air&#xD;
&#xD;
               -  Performance status: Karnofsky score ≥60%&#xD;
&#xD;
          4. Donor available aged ≥16 years&#xD;
&#xD;
          5. Needs an urgent transplant where a 10/10 HLA matched sibling or unrelated donor is&#xD;
             unavailable in a timely manner. An unrelated donor search is not required for a&#xD;
             patient to be eligible if the clinical situation dictates an urgent transplant.&#xD;
             Clinical urgency is defined as 6-8 weeks from referral to transplant centre or low&#xD;
             likelihood of finding a matched unrelated donor&#xD;
&#xD;
          6. HLA typing will be performed at high resolution (allelic) for the HLA-A, HLA-B,&#xD;
             HLA-Cw, HLA-DRB1 and HLA-DQB1 loci. A minimum match of 5/10 is required&#xD;
&#xD;
          7. The donor and recipient must be identical as determined by high resolution typing at&#xD;
             at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw,&#xD;
             HLA-DRB1 and HLA-DQB1. Fulfilment of this criterion is sufficient evidence that the&#xD;
             donor and recipient share one HLA haplotype and typing of additional family members is&#xD;
             not required.&#xD;
&#xD;
          8. Patient must have received cytotoxic chemotherapy within 3 months of the consent date&#xD;
             (measured from the start date of the most recent cycle of chemotherapy) except&#xD;
             patients with aplastic anaemia, unless otherwise agreed by the TMG (see section&#xD;
             5.3.4). The use of monoclonal antibody therapy may be considered cytotoxic&#xD;
             chemotherapy, but must be agreed by the TMG&#xD;
&#xD;
          9. Written informed consent&#xD;
&#xD;
        Donor Inclusion Criteria&#xD;
&#xD;
          1. Donor must be an HLA-haploidentical first degree relative of the patient. Eligible&#xD;
             donors include biological parents, siblings, children or half-siblings&#xD;
&#xD;
          2. Age ≥16 years&#xD;
&#xD;
          3. Donors must meet the collection centre's usual selection criteria for related&#xD;
             allogeneic HPC donors&#xD;
&#xD;
        Patient Exclusion Criteria&#xD;
&#xD;
          1. HLA matched, related donor able to donate&#xD;
&#xD;
          2. Autologous haematopoietic stem cell transplant &lt;3 months prior to enrolment&#xD;
&#xD;
          3. Pregnancy or breastfeeding&#xD;
&#xD;
          4. Uncontrolled bacterial, viral or fungal infection (currently taking medication with&#xD;
             evidence of progression of clinical symptoms or radiological findings), the inclusion&#xD;
             of patients with an uncontrolled viral or fungal infection can be agreed by the TMG&#xD;
&#xD;
          5. Serious psychiatric or psychological disorders&#xD;
&#xD;
          6. Absence or inability to provide informed consent&#xD;
&#xD;
          7. Severe comorbidity (HCT-CI comorbidity score of 3 or more) or disease that prevents&#xD;
             treatment with chemotherapy, unless otherwise agreed by the TMG&#xD;
&#xD;
          8. Positive anti-donor HLA antibody&#xD;
&#xD;
          9. Unable to receive 2Gy TBI (RIC pathway) or 12Gy TBI (MAC pathway)&#xD;
&#xD;
         10. Patients with graft rejection following a previous allograft from either adult or cord&#xD;
             blood donors&#xD;
&#xD;
        Donor Exclusion Criteria&#xD;
&#xD;
          1. Positive anti-donor HLA antibody in the recipient&#xD;
&#xD;
          2. Pregnancy or recent birth (within 6 months prior to donating cells)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Kavita Raj</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Heartlands</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire, Sheffield &amp; Weston Park</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical transplant</keyword>
  <keyword>Haematological malignancy</keyword>
  <keyword>Myeloablative</keyword>
  <keyword>Reduced intensity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

